Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index P53 and bcl-2 immunoreactivity

Journal of Urology

Volumn 159, Issue 5, 1998, Pages 1437-1443

  Grossfeld, Gary D ^a   Olumi, Aria F ^a   Connolly, John A ^a   Chew, Karen ^a   Gibney, Jennifer ^a   Bhargava, Vivek ^a   Waldman, Frederic M ^a   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Local; Neoplasm recurrence; Prostatectomy; Prostatic neoplasms; Radiotherapy

Indexed keywords

KI 67 ANTIGEN;

ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROSTATECTOMY; TUMOR RECURRENCE;

EID: 0032458445     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199805000-00004     Document Type: Article

References (26)

1. Takayama, T. K. and Lange, P. H.: Radiation therapy for local recurrence of prostate cancer after radical prostatectomy. Urol. Clin. N. Amer., 21: 687, 1994.
2. Scardino, P. T. and Wheeler, T. M.: Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr., 7: 95, 1988.
3. Schellhammer, P. F. and el-Mahdi, A. M.: Local failure and related complications after definitive treatment of carcinoma of the prostate by irradiation or surgery. Urol. Clin. N. Amer., 17: 835, 1990.
4. Paulovich, A. G., Toczyski, D. P. and Hartwell, L. H.: When checkpoints fail. Cell, 88: 315, 1997.
5. Wheeler, J. A., Zagars, G. K. and Ayala, A. G.: Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression. Cancer, 71: 3783, 1993.
6. Stamey, T. A., Ferrari, M. K. and Schmid, H. P.: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J. Urol., 150: 1856, 1993.
7. Gerdes, J., Becker, M. H., Key, G. and Cattoretti, G.: Immuno-histological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J. Path., 168: 85, 1992.
8. Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R. D. and Korsmeyer, S. J.: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348: 334, 1990.
9. Levine, A. J.: p53, the cellular gatekeeper for growth and division. Cell, 88: 323, 1997.
10. Moul, J. W., Bettencourt, M. C., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Bauer, J. J.: Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery, 120: 159, 1996.
11. Bubendorf, L., Sauter, G., Moch, H., Jordan, P., Blochlinger, A., Gasser, T. C. and Mihatsch, M. J.: Prognostic significance of Bcl-2 in clinically localized prostate cancer. Amer. J. Path., 148: 1557, 1996.
12. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C. and Conti, C. J.: p53 Protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657, 1993.
13. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S. and Moul, J. W.: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J. Urol., 156: 1511, 1996.
14. Connolly, J. A., Presti, J. C., Jr., Cher, M. L., Chew, K., Shinohara, K. and Carroll, P. R.: Accelerated tumor proliferation rates in locally recurrent prostate cancer after radical prostatectomy. J. Urol., 158: 515, 1997.
15. Stackhouse, G. B., Sesterhenn, I., Mostofi, F. K., McLeod, D. G. and Moul, J. W.: Immunohistochemical staining (IHC) for p53 and bcl-2 in needle biopsies of the prostate does not appear to predict clinical recurrence rate after radical prostatectomy. Proc. AACR, 38: 256, 1997.
16. Gleason, D. F.: Histologic grading and clinical staging of prostatic carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea & Febiger, chapt. 9, pp 171-198, 1977.
17. Yang, G., Stapleton, A. M. F., Wheeler, T. M., Truong, L. D., Timme, T. L., Scardino, P. T. and Thompson, T. C.: Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin. Cancer Res., 2: 399, 1996.
18. Hanks, G. E., Lee, W. R. and Schultheiss, T. E.: Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J. Urol., 154: 456, 1995.
19. Hancock, S. L., Cox, R. S. and Bagshaw, M. A.: Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University. J. Urol., 154: 1412, 1995.
20. Fowler, J. E., Jr., Pandey, P., Braswell, N. T. and Seaver, L.: Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer. Surgery, 116: 302, 1994.
21. Tlsty, T. D., Briot, A., Gualberto, A., Hall, I., Hess, S., Hixon, M., Kuppuswamy, D., Romanov, S., Sage, M. and White, A.: Genomic instability and cancer. Mutat. Res., 337: 1, 1995.
22. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H. and Folkman, J.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315, 1994.
23. Aprikian, A. G., Sarkis, A. S., Fair, W. R., Zhang, Z. F., Fuks, Z. and Cordon-Cardo, C.: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J. Urol., 151: 1276, 1994.
24. Berner, A., Geitvik, G., Karlsen, F., Fossa, S. D., Nesland, J. M. and Borresen, A. L.: TP53 mutations in prostatic cancer. Analysis of pre-and post-treatment archival formalin-fixed tumour tissue. J. Path., 176: 299, 1995.
25. Rideout, W. M. D., Coetzee, G. A., Olumi, A. F. and Jones, P. A.: 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science, 249: 1288, 1990.
26. Heidenberg, H. B., Sesterhenn, I. A., Gaddipati, J. P., Weghorst, C. M., Buzard, G. S., Moul, J. W. and Srivastava, S.: Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol., 154: 414, 1995.